The Carlyle Group Inc. Stock Price, News & Analysis

Resonetics has acquired the nitinol gun drilling operations and related assets from Medical Component Specialists' (MCS) New Boston, NH facility. The acquisition strengthens Resonetics' U.S.-based nitinol strategy and enhances their supply chain resilience. Gun drilling, a specialized machining process creating precision holes in bars, is fundamental for producing high-performance nitinol tubing used in medical devices.

This move follows Resonetics' recent investments in melt capacity, raw materials, and the acquisition of former Memry Corp. and SAES Smart Materials, establishing the industry's most comprehensive nitinol portfolio. The company aims to improve material availability, reduce lead times, and maintain its position as an open-source supplier to medical device OEMs and contract manufacturers.

Carlyle and SK Capital Partners have amended their agreement to acquire bluebird bio (NASDAQ: BLUE). Under the updated terms, stockholders can now choose between two options: (1) the original offer of $3.00 per share plus a CVR worth $6.84 tied to sales milestones, or (2) a new alternative of $5.00 per share with no CVR.

Important updates require stockholders who previously tendered shares to re-tender their shares with a new election. The tender offer expires on May 29, 2025. The board unanimously recommends stockholders to tender their shares, warning that without majority participation, bluebird risks defaulting on Hercules Capital loans, potentially leading to bankruptcy where shareholders might receive nothing.

bluebird bio (NASDAQ: BLUE) has amended its merger agreement with Carlyle (NASDAQ: CG) and SK Capital Partners. Under the new terms, stockholders can choose between two options: (1) the original offer of $3.00 per share plus a CVR of $6.84 payable upon achieving net sales milestone, or (2) $5.00 per share in cash with no CVR. The board unanimously recommends stockholders to tender their shares, warning that without majority support, the company risks defaulting on loans with Hercules Capital, potentially leading to bankruptcy. The tender offer deadline has been extended to May 29, 2025. As of May 13, approximately 2,281,724 shares have been tendered. All regulatory approvals have been received, and the transaction is expected to close promptly after successful completion of the tender offer.

Carlyle and SK Capital have received all necessary regulatory approvals to proceed with the acquisition of bluebird bio (NASDAQ: BLUE). The merger is expected to complete following a tender offer expiring on May 12, 2025. Shareholders will receive $3.00 per share in cash upfront and a contingent value right (CVR) of $6.84 per share upon achieving a net sales milestone, totaling a potential value of $9.84 per share.

The bluebird Board unanimously recommends shareholders to tender their shares, warning that without majority participation, the company risks defaulting on loan agreements with Hercules Capital. The Board emphasizes this transaction represents the only viable option for stockholders to receive value for their shares, as bankruptcy or liquidation would likely result in no shareholder compensation.

Yieldstreet has announced the launch of Yieldstreet 360 Managed Portfolios, the first automated private markets investing solution. The platform aims to democratize access to private equity, private credit, and real estate investments through diversified portfolios tailored to individual investors' goals.

The launch comes as private markets have grown from $9.7 trillion in 2012 to $24.4 trillion in 2023. The solution will feature investments from Goldman Sachs Asset Management, Carlyle, and StepStone, with strategies advised by Wilshire. The platform addresses traditional barriers like high investment minimums and complex structures, offering automated investment management and real-time performance tracking.

Available to accredited investors later this year, Yieldstreet 360 will provide exposure to thousands of underlying assets through a single solution, with options ranging from income-focused to growth-oriented approaches.

SoftBank Group has announced the acquisition of Ampere Computing, a silicon design company, in an all-cash transaction valued at $6.5 billion. The deal involves Carlyle (CG) and Oracle Corp. selling their positions in Ampere.

Under the agreement, Ampere will operate as a wholly owned subsidiary of SoftBank Group while retaining its name. The acquisition aligns with SoftBank's expansion in AI infrastructure investments, including ventures like Cristal intelligence and Stargate.

Founded in Silicon Valley in 2018, Ampere specializes in cloud-native computing and sustainable AI compute, offering multiple products for cloud workloads. The transaction is expected to close in the second half of 2025, subject to regulatory approvals. Ampere will maintain its headquarters in Santa Clara, CA.